ReviewFrontiers in molecular biosciences2020
Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research.
Review in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Navigating the Landscape of Cytometry-Based Single-Cell Proteomics: Quantification, Annotation, and Resources.International journal of molecular sciences · 2026Review
- AutoFlow: an interactive Shiny app for supervised and unsupervised flow cytometry analysis.Bioinformatics (Oxford, England) · 2026Article
- ImmunoPheno: A Computational Framework for Data-Driven Design and Analysis of Immunophenotyping Experiments.bioRxiv : the preprint server for biology · 2026Article
- Development and computational analysis of high dimensional spectral flow cytometry data for the resolution of innate lymphoid cells in the mammary tumor microenvironment.Frontiers in immunology · 2026Article
- A standardized single-tube 17-color spectral flow cytometry workflow for integrated immunophenotyping of human PBMCs and mixed co-culture systems.Frontiers in immunology · 2026Article
- Ultra-high-scale cytometry-based cellular interaction mapping.Nature methods · 2025Article
- Beyond the Limits: How Is Spectral Flow Cytometry Reshaping the Clinical Landscape and What Is Coming Next?Cells · 2025Review
- Multicolor Flow Cytometry for Immune Characterization of Omental Metastasis in Peritoneal Carcinomatosis Mice Models.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Flow cytometric detection of leukemic stem cells in Acute Myeloid Leukemia: current status and future directions.Frontiers in pharmacology · 2025Review
- Article
- Review
- Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective.Molecular cancer · 2024Review
- Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment.Nature reviews. Cancer · 2024Review
- Increasing Signal Intensity of Fluorescent Oligo-Labeled Antibodies to Enable Combination Multiplexing.Bioconjugate chemistry · 2024Article
- Increasing Signal Intensity of Fluorescent Oligo-Labeled Antibodies to Enable Combination Multiplexing.bioRxiv : the preprint server for biology · 2024Article
- Applications of Flow Cytometry in Drug Discovery and Translational Research.International journal of molecular sciences · 2024Review
- Spectral Flow Cytometry Methods and Pipelines for Comprehensive Immunoprofiling of Human Peripheral Blood and Bone Marrow.Cancer research communications · 2024Article
- Biomarkers in Ovarian Cancer: Towards Personalized Medicine.Proteomes · 2024Review
- An Overview of Advances in Rare Cancer Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- State-of-the-art cytometry in the search of novel biomarkers in digestive cancers.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Nobel Prize-deserving concept of blocking inhibitory pathways in T cells, to unleash their anti-tumoral capacity, became one of the pillars of cancer treatment in the last decade and has resulted in durable clinical responses for multiple cancer types. Currently, two of the most important goals in cancer immunotherapy are to understand the mechanisms resulting in failure to checkpoint blockade and to identify predictive immunological biomarkers that correlate to treatment response, disease progression or adverse effects. The identification and validation of biomarkers for routine clinical use is not only critical to monitor disease or treatment progression, but also to personalize and develop new therapies. To achieve these goals, powerful research tools are needed. Flow cytometry stands as one of the most successful single-cell analytical tools used to characterize immune cell phenotypes to monitor solid tumors, hematological malignancies, minimal residual disease or metastatic progression. This technology has been fundamental in diagnosis, treatment and translational research in cancer clinical trials. Most recently, the need to evaluate simultaneously more features in each cell has pushed the field to implement more powerful adaptations beyond conventional flow cytometry, including Full Spectrum Flow Cytometry (FSFC). FSFC captures the full emission spectrum of fluorescent molecules using arrays of highly sensitive light detectors, and to date has enabled characterization of 40 parameters in a single sample. We will summarize the contributions of this technology to the advancement of research in immunotherapy studies and discuss best practices to obtain reliable, robust and reproducible FSFC results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.